JAAOS - 2026-05-01 - Journal Article
Functional Outcomes of Reverse Shoulder Arthroplasty and Allograft-Prosthetic Composite in Oncologic Patients.
van der Linden LR, Gonzalez MR, Gasho JO, Ubong SE, Elhassan BT, Kang HP, Lozano Calderón SA
Topics
Key Takeaway
Oncologic rTSA patients had 22% dislocation and 52% reoperation rates versus 0% and 10% in matched nononcologic controls, yet rTSA-APC achieved superior MSTS scores over rTSA-alone (80% vs. 37%, p=0.04) despite higher axillary nerve resection rates.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study compared complications and functional outcomes of rTSA with and without allograft-prosthetic composite for proximal humerus tumor resection against a propensity score-matched nononcologic cohort. Oncologic patients had significantly higher dislocation (22% vs. 0%), reoperation (52% vs. 10%), and revision (30% vs. 5%) rates, with lower MSTS scores (70% vs. 90%, p=0.001). Within the oncologic group, rTSA-APC patients achieved higher MSTS scores than rTSA-alone (80% vs. 37%, p=0.04) despite more frequent axillary nerve resection (38% vs. 0%, p=0.01).
Key Limitation
The rTSA-APC subgroup contains only 8 patients, making the functional outcome comparison statistically fragile and insufficient to draw definitive reconstructive preference conclusions.
Original Abstract
INTRODUCTION
Reverse total shoulder arthroplasty (rTSA) is a feasible reconstruction technique for proximal humerus tumors and can be combined with allograft-prosthetic composite (rTSA-APC) for extensive lesions. We assessed postoperative complications and functional outcomes after rTSA with and without allograft prosthetic composites for oncologic indications, comparing them with a matched nononcologic cohort.
METHODS
Twenty-three patients who underwent rTSA with or without allograft prosthetic composites after proximal humerus tumor resection between 2010 and 2022 were included. We defined two groups in the oncologic cohort: rTSA (15 patients) and rTSA-APC (8 patients). Implant failure was assessed using the Henderson classification and outcomes with the Musculoskeletal Tumor Society score. Outcomes were compared with those of a propensity score-matched nononcologic cohort.
RESULTS
Oncologic patients exhibited higher rates of dislocation (22% vs. 0%), axillary nerve resection (13% vs. 0%), reoperation (52% vs. 10%), and revision surgery (30% vs. 5%) compared with nononcologic patients. Within the oncologic cohort, axillary nerve resection was more frequent in the rTSA-APC group (38% vs. 0%, P = 0.01); no other differences were seen between groups. Two-year dislocation-, reoperation-, and revision-free survival rates were higher in the nononcologic cohort. No differences in survival rates were observed between the rTSA and rTSA-APC groups. Shoulder range of motion was similar between groups. Median Musculoskeletal Tumor Society scores were higher in nononcologic patients compared with oncologic ones (90% vs. 70%; P = 0.001) and in rTSA-APC patients compared with rTSA patients (80% vs. 37%; P = 0.04).
CONCLUSION
Oncologic patients overall had more complications and lower functional scores compared with nononcologic patients. Within the oncologic cohort, rTSA-APC patients achieved better functional outcomes than rTSA-only patients, despite experiencing higher complication rates. Surgical approaches should be individualized based on the anatomic defect.
LEVEL OF EVIDENCE
III.